Chiasma, Inc. and Lonza have entered into a commercial supply agreement for Chiasma’s oral somatostatin analog candidate, MYCAPSSA.   Chiasma is conducting a Phase III trial under a Special Protocol Assessment agreement reached with the U.S. FDA for its octreotide capsules product candidate, MYCAPSSA, for the maintenance therapy of adult patients with acromegaly. If approved, Chiasma believes MYCAPSSA will be the first oral somatostatin analog for the treatment of acromegaly, a disorder that t...